Strategy | Costs per HCW (€) | QALYs | Incremental C/E ratio |
Baseline-US | 126.60 | 23.2292 | |
European | 155.10 | 23.2409 | Weakly dominated* |
Alternative-US | 178.50 | 23.2549 | €2020 |
French | 181.40 | 23.2396 | Strongly dominated† |
*A weakly dominated strategy a higher incremental C/E ratio than that of a more effective alternative strategy—that is, the incremental C/E ratio of the European strategy vs the baseline-US is higher than the incremental C/E ratio of the alternative-US strategy vs the European strategy.
†A strongly dominated strategy indicates a higher cost than that of a more effective alternative strategy—that is, the French strategy is associated with a higher cost and a lower utility compared with the alternative-US strategy.
C/E, cost-effectiveness; HCV, hepatitis C virus; HCW, healthcare worker; QALY, quality-adjusted life year.